Medians of overall survival (months) for the three genes, <i>ERS1</i>, <i>ERS2</i>, and <i>CYP19A1</i> (Low and High, N = 48) and aromatase protein, ARO (Low N = 43 and High N = 42), when categorizing their values into low and high expression values (lower and higher expression than median).

<p>Kaplan-Meier Log Rank and Mann-Whitney p-values when comparing Low vs. High groups are also listed. T = Tumor; NT = Non-tumor.</p><p>Medians of overall survival (months) for the three genes, <i>ERS1</i>, <i>ERS2</i>, and <i>CYP19A1</i> (Low and High, N = 48) and aromatase protein, ARO (Low N = 43 and High N = 42), when categorizing their values into low and high expression values (lower and higher expression than median).</p

Medians for the three genes (<i>ERS1</i>, <i>ERS2</i>, and <i>CYP19A1</i>) relative expression (RQ) measures, N = 96, and aromatase protein concentration, N = 85.

<p>Also includes p-values for Man-Whitney tumor/non-tumor RQ comparison.</p><p>T = Tumor; NT = Non-tumor.</p><p>ARO* =  Protein concentration ELISA values, ng/ml.</p><p>Medians for the three genes (<i>ERS1</i>, <i>ERS2</i>, and <i>CYP19A1</i>) relative expression (RQ) measures, N = 96, and aromatase protein concentration, N = 85.</p

Kaplan-Meier survival curves when considering gene mRNA expression levels (<i>ERS1, ERS2</i> and <i>CYP19A1</i>), or protein concentration (ARO), as discriminating factor.

<p>The patient sample is divided into Low and High (lower and higher expression than median). Panels: a) <i>ERS1</i>and <i>ERS2</i>, b) <i>CYP19A1</i> and ARO, and c) <i>ERS1+ERS2</i> and CYP19A1 + ARO.</p

Statistics of overall survival (months) of tumor samples for <i>ERS1</i> gene expression, <i>ERS2</i> gene expression, <i>CYP19A1</i> gene expression and aromatase protein concentration (ARO) for each combination of low and high expression groups (lower and higher than median).

<p>Kaplan-Meier Log Rank (Mantel-Cox) and Kruskal-Wallis p-values are listed when comparing these different categories. N: Patient number.</p><p>Statistics of overall survival (months) of tumor samples for <i>ERS1</i> gene expression, <i>ERS2</i> gene expression, <i>CYP19A1</i> gene expression and aromatase protein concentration (ARO) for each combination of low and high expression groups (lower and higher than median).</p

Patient Characteristics.

<p>*<i>Chemotherapy.</i></p><p>Patient Characteristics.</p